Erlotinib intermediates manufacturer
Regorafenib powder 755037-03-7 for Anti cancer Regorafenib Monohydrate
Regorafenib is a multi-targeted multi-kinase inhibitor of tyrosine kinase. More than ten targets are targeted: VEGFR1, VEGFR2, VEGFR3, TIE-1, TIE-2, RAF-1, BRAF, BRAFV600, KIT, RET, PDGFR, FGFR and so on.
Regufenib is a multikinase inhibitor that inhibits tumor growth by inhibiting tumor angiogenesis, tumor cell renewal, and maintaining tumor microenvironment. Including VEGF receptors 1-3, KIT, PDGFR-alpha, PDGFR-beta, RET, FGFR1 and 2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF-V600E, SAPK2, PTK5 and Abl.
Regorafenib is a kinase inhibitor that has been used previously for fluoropyrimidine-based, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF treatment, an anti-EGFR-treated metastasis Treatment of colorectal cancer (CRC) patients.
